Omeros Corporation (OMER)
NASDAQ: OMER · Real-Time Price · USD
14.53
-0.14 (-0.95%)
Apr 29, 2026, 10:23 AM EDT - Market open
Omeros Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
175
Market Cap
1.05B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.72B |
| Xeris Biopharma Holdings | 291.85M |
| KalVista Pharmaceuticals | 73.62M |
| Septerna | 45.95M |
| EyePoint | 31.37M |
| uniQure | 16.10M |
| Zenas BioPharma | 10.00M |
| Inventiva | 7.94M |
OMER News
- 13 days ago - CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) - Business Wire
- 4 weeks ago - Omeros Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results - Business Wire
- 4 weeks ago - Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026 - Business Wire
- 5 weeks ago - Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment - Business Wire
- 2 months ago - Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program - Business Wire
- 3 months ago - Omeros Announces First Commercial Sales of YARTEMLEA® - Business Wire
- 3 months ago - Omeros prices transplant complication drug at $36,000 per dose - Reuters